MET and neoplasm: For example, the inhibition of the HGF/c-Met signalling pathway is a compelling therapy to interfere with tumour growth and angiogenesis.52 Specific protagonists to VE-Cadherin could be used to potentially normalise the “leaky vasculature” caused by VEGFA upregulation, which are independent of one another.